Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study.

Andrew M Donson Kelsey C Bertrand Kent A Riemondy Dexiang Gao Yonghua Zhuang Bridget Sanford Gregory A Norris Rebecca J ChapmanRui FuNicholas Willard Andrea M Griesinger Graziella Ribeiro de Sousa Vladimir AmaniEnrique GrimaldoTodd C HankinsonFfyona BookerMartin Sill Richard G Grundy Kristian W PajtlerDavid W EllisonNicholas K Foreman Timothy A Ritzmann

Published in: Neuro-oncology (2023)

This study provides clinically and preclinically-actionable insights into the biology of PFA recurrence. The hypomethylation predisposition signature in PFA is a potential risk-classifier for trial stratification. We show that the cellular heterogeneity of PFAs evolves largely because of genetic evolution of neoplastic cells.

Keyphrases

induced apoptosis
free survival
copy number
clinical trial
study protocol
randomized controlled trial
single cell
cell cycle arrest
dna methylation
genome wide
phase iii
oxidative stress
cell proliferation
climate change
human health
risk assessment
breast cancer risk